

Errata

Erratum to: Fady B. Geara, MD, PhD; Ritsuko Komaki, MD; Susan L. Tucker, PhD; Penny Perkins, PhD; Elizabeth L. Travis, PhD; James D. Cox, MD. 2149 Determinants of Lung Fibrosis After Chemoradiation for Small Cell Carcinoma of the Lung: Evidence for Inherent Interindividual Variation. *Int J Radiat Oncol Biol Phys* 1996;36(suppl):350.



Penny Perkins, Ph.D. notified the International Journal of Radiation Oncology Biology and Physics that her name was included in the author line of the above meeting abstract. Dr. Perkins stated that she did not generate the statistics in the abstract, and was not aware of the submission. She requested removal of her name from the author line. Therefore, the author line of this abstract should be cited as follows:

Fady B. Geara, MD, PhD; Ritsuko Komaki, MD; Susan L. Tucker, PhD; Elizabeth L. Travis, PhD; James D. Cox, MD.

<https://doi.org/10.1016/j.ijrobp.2019.09.035>

DOI of original article: [https://doi.org/10.1016/S0360-3016\(97\)85724-0](https://doi.org/10.1016/S0360-3016(97)85724-0).

Erratum to: Lee AW, Ng WT, Pan JJ, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys* 2019;105:567-580



In [Table 2](#) of the above-referenced article, the Desirable dose of Thyroid should have read “V50 <60%” and the Acceptable dose for Thyroid should read “VS60 <10 cm³” matching both the Table and the rest of the manuscript. The corrected table is below. The authors regret the error.

OAR			Acceptance criteria					
			Desirable dose			Acceptable dose		
Organ	Priority	n/N, % agree (of those who voted)	Disagree, (alternative priority) - No. voting/ N	Specification	Dose	n/N, % agree (of those who voted)	Dose	GRADE of recommendation
Brain stem	1	17/17, 100		D0.03 cm³	≤54 Gy	18/20, 90	≤60 Gy*	19/21, 90 High/Moderate
Spinal cord	1	17/17, 100		D0.03 cm³	≤45 Gy	20/20, 100	≤50 Gy	20/21, 95 High
Optic chiasm	1	16/17, 94	(3) - 1/17	D0.03 cm³	≤54 Gy	14/15, 93	≤60 Gy	14/17, 82 High/Moderate
GTV-T & GTV-N	2	10/16, 63	(1) - 6/16	Min	≥68.6 Gy (98% dose)	14/18, 78	66.5 Gy (95% dose)	16/20, 80 Moderate
PTV dose prescription	2	15/17, 88	(1) - 1/17 (4) - 1/17	Prescription dose	PTV70, 63, 60, 56 = 35# PTV 69.96, 63, 60, 54 = 33#	17/21, 81		

(continued on next page)

Table 2 (continued)

OAR				Acceptance criteria					
				Desirable dose			Acceptable dose		
Organ	Priority	n/N, % agree (of those who voted)	Disagree, (alternative priority) - No. voting/ N	Specification	Dose	n/N, % agree (of those who voted)	Dose	n/N, % agree (of those who voted)	GRADE of recommendation
PTV min	2	13/15, 87	(1) - 1/15 (4) - 1/15	Min	≥95% PTV 100% or ≥99% PTV ≥93% dose	19/20, 95	95% PTV ≥ 95% dose	18/20, 90	High/Moderate
PTV hotspot	2	14/15, 93	(4) - 1/15	Max	<5% PTV70 ≥ 75 Gy or ≤10% PTV70 ≥77 Gy	18/21, 86	<10% PTV70 ≥75 Gy or ≤20% PTV70 90 ≥77 Gy	18/20, 90	Moderate
Temporal lobe	2	11/17, 65	(1) - 1/17 (3) - 4/17 (5) - 1/17	D0.03 cm³	≤65 Gy for early stage and ≤70 Gy for late stage	17/20, 85	≤72 Gy	13/21, 62	Moderate
Optic nerve	3 Bilateral: 1	12/17, 71	(1) - 2/17 (2) - 2/17	D0.03 cm³	≤54 Gy	19/20, 95	≤60 Gy	21/22, 95	High/Moderate
Parotid gland	4	12/17, 71	(3) - 1/17 (2) - 2/17 (3) - 2/17 (5) - 1/17	Mean	<26 Gy	18/20, 90	<30 Gy (at least 1 gland)	18/22, 82	Moderate
Mandible and TM joint	4	14/17, 82	(3) - 2/17 (5) - 1/17	D2%	≤70 Gy	18/19, 95	≤75 Gy	14/21, 67	Moderate
Brachial plexus	3	13/15, 87	(2) - 1/15 (5) - 1/15	D0.03 cm³	<66 Gy	16/18, 89	≤70 Gy	17/20, 85	Moderate
Pituitary and hypothalamus	4	11/14, 79	(2) - 1/14 (3) - 1/14 (5) - 1/14	D0.03 cm³	≤60 Gy	11/14, 79	≤65 Gy	13/15, 87	Moderate / Low
Lens	3	12/17, 71	(1) - 1/17 (4) - 2/17 (5) - 2/17	D0.03 cm³	≤6 Gy	18/20, 90	≤15 Gy	18/22, 82	Moderate
Eyeball	3	14/17, 82	(2) - 2/17 (4) - 1/17	Mean	<35 Gy	18/20, 90	≤50 Gy (D0.03 cm³)	16/21, 76	Moderate
Cochlea	4	13/17, 76	(2) - 2/17 (3) - 2/17	Mean	≤45 Gy	18/20, 90	≤55 Gy	19/22, 86	Moderate
Glottic larynx	4	16/17, 94	(3) - 1/17	Mean	≤35 Gy	15/20, 75	≤50 Gy (D2%)	10/22, 45	Moderate
Postcricoid pharynx, esophagus (within field)	4	13/17, 76	(3) - 2/17 (5) - 2/17	Mean	≤45 Gy	17/20, 85	≤55 Gy	14/22, 64	Moderate Moderate/Low
Oral cavity (excluding PTV)	4	13/17, 76	(3) - 2/17 (5) - 2/17	Mean	<40 Gy	14/20, 70	<50 Gy	17/22, 77	Moderate/Low
Submandibular gland	4	13/14, 93	(5) - 1/14	Mean	<35 Gy	17/21, 81			Moderate
Thyroid	4	12/14, 86	(3) - 1/14 (5) - 1/14		V ₅₀ <60%	14/16, 88	VS ₆₀ <10 cc	16/18, 89	Moderate/Low

Abbreviations: GRADE = Grading of Recommendations Assessment, Development, and Evaluation; GTV-N = gross tumor volume for lymph nodes; GTV-T = gross tumor volume for tumor; OAR = organ at risk; PTV = planning target volume; TM = temporomandibular.

* A recent study by Huang et al¹⁹ suggested a D_{max} of 67.4 Gy (equivalent dose in 2-Gy fractions) as the dose constraint for brain stem. Although this may be discussed as an option for patients with tumors encroaching on the brain stem, a conservative dose acceptance criterion (to aim for a D_{0.03cc} planning risk volume dose ≤54 Gy and maximum acceptance criterion of 60 Gy) was preferred among our panel (25 of 25 [100%] of those who responded to this special vote) for this general guideline until more robust validation becomes available.

<https://doi.org/10.1016/j.ijrobp.2019.09.030>

DOI of original article: <https://doi.org/10.1016/j.ijrobp.2019.06.2540>.